Author:
Wroblewski Joanne M.,Yannelli John R.
Reference110 articles.
1. Arienti F, Sule-Suso J, Belli F et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955–63.
2. Aebersold P, Hyatt C, Johnson S et al. Lysis of autologous melanoma cells by TIL: association with clinical responses. J Natl Cancer Inst 1991; 83: 932–7.
3. Antonio SJ, Seigne J, Diaz J et al. Phase I trial of a B7–1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic IL-2 in patients with metastasis renal cell carcinoma. J Urol 2002; 167: 1995–2000.
4. Bain C, Merrouch Y, Puiseux I. B7.1 gene transduction of human renal-cell carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 1996; 67: 769–76.
5. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastasis melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–8.